Jefferies Maintains Buy Rating on Incyte

According to Jefferies, Incyte

Buy rating is maintained. Jefferies said that overall survival data highlighted during the weekend at the American Society of Hematology (

) meeting from the COMFORT-1 study should help Jakafi gain rapid adoption among physicians. “Separately, data on a new competitor (LY2784544) solidify Jakafi's best-in-class positioning.” Incyte closed on Friday at $13.60.